trazodone has been researched along with Anxiety in 40 studies
Trazodone: A serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major depressive disorders and other subsets of depressive disorders. It is generally more useful in depressive disorders associated with insomnia and anxiety. This drug does not aggravate psychotic symptoms in patients with schizophrenia or schizoaffective disorders. (From AMA Drug Evaluations Annual, 1994, p309)
trazodone : An N-arylpiperazine in which one nitrogen is substituted by a 3-chlorophenyl group, while the other is substituted by a 3-(3-oxo[1,2,4]triazolo[4,3-a]pyridin-2(3H)-yl)propyl group.
Anxiety: Feelings or emotions of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "OBJECTIVE To evaluate the efficacy of a single dose of trazodone for reducing anxiety in cats during transport to a veterinary hospital and facilitating handling during veterinary examination." | 9.22 | Efficacy of a single dose of trazodone hydrochloride given to cats prior to veterinary visits to reduce signs of transport- and examination-related anxiety. ( Frantz, EM; Griffith, E; Gruen, ME; Harden, LB; Orlando, JM; Sherman, BL; Stevens, BJ, 2016) |
| "Trazodone significantly improved fibromyalgia severity and associated symptomatology." | 9.15 | Trazodone plus pregabalin combination in the treatment of fibromyalgia: a two-phase, 24-week, open-label uncontrolled study. ( Calandre, EP; Molina-Barea, R; Morillas-Arques, P; Rico-Villademoros, F; Rodriguez-Lopez, CM, 2011) |
| "Early human pharmaco-EEG and subsequent sleep laboratory studies identified trazodone, a 5-HT(2) antagonist and 5-HT reuptake inhibitor (SARI), as an antidepressant with therapeutic effects on its target symptoms depressed mood, anxiety and insomnia." | 9.10 | Confirmation of the neurophysiologically predicted therapeutic effects of trazodone on its target symptoms depression, anxiety and insomnia by postmarketing clinical studies with a controlled-release formulation in depressed outpatients. ( Anderer, P; Arnold, O; Saletu, B; Saletu-Zyhlarz, GM, 2003) |
| " Twenty-eight inpatients with a diagnosis of endogenous depression received either trazodone, imipramine, or placebo." | 9.04 | Trazodone, a new antidepressant: efficacy and safety in endogenous depression. ( Kellams, JJ; Klapper, MH; Small, JG, 1979) |
| "Due diligence and meticulous attention to detail needs to be exercised to uncover drug interactions as potential causes of lethal and nonlethal patient symptomatology, as in this case of syncope caused by concomitant use of trazodone and a widely prescribed medication, omeprazole." | 8.91 | Trazodone and omeprazole interaction causing frequent second-degree Mobitz type 1 atrioventricular (AV) block (Wenckebach phenomenon) and syncope: a case report and literature review. ( Akinseye, OA; Alfishawy, M; Bakshi, S; Radparvar, F, 2015) |
| " Trazodone turned out to be an efficacious medicine in the therapy of adjustment disorders." | 7.73 | [The efficacy and safety of trazodone in the treatment of adjustment disorders--naturalistic research]. ( Florkowski, A; Gałecki, P; Zboralski, K, 2005) |
| "An additional insomnia analysis assessed whether the efficacy of TzCOAD is influenced by improvements in insomnia or baseline severity of insomnia." | 6.74 | The efficacy and tolerability of once-daily controlled-release trazodone for depressed mood, anxiety, insomnia, and suicidality in major depressive disorder. ( Gibertini, M; Gossen, ER; Rozova, A; Sheehan, DV, 2009) |
| "Antidepressant-induced jitteriness/anxiety syndrome is characterized as anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia, and (hypo)mania, which appear immediately after initiation or increased dosage of an antidepressant." | 5.91 | Jitteriness/anxiety syndrome caused by coadministration of celecoxib, a selective COX-2 inhibitor, with escitalopram and trazodone in a patient with depression and spondylolisthesis. ( Kanno, M; Noto, K; Shirata, T; Suzuki, A; Yano, S, 2023) |
| "Obstructive sleep apnea (OSA) is a highly prevalent type of sleep-disordered breathing, which is often comorbid with affective disorders such as anxiety." | 5.91 | Successful treatment of auto-trilevel positive airway pressure plus trazodone for obstructive sleep apnea complicated by anxiety disorder: a case report. ( He, X; Lang, Q; Pei, ZM; Yan, HY, 2023) |
| "Trazodone significantly improved fibromyalgia severity and associated symptomatology." | 5.15 | Trazodone plus pregabalin combination in the treatment of fibromyalgia: a two-phase, 24-week, open-label uncontrolled study. ( Calandre, EP; Molina-Barea, R; Morillas-Arques, P; Rico-Villademoros, F; Rodriguez-Lopez, CM, 2011) |
| "Early human pharmaco-EEG and subsequent sleep laboratory studies identified trazodone, a 5-HT(2) antagonist and 5-HT reuptake inhibitor (SARI), as an antidepressant with therapeutic effects on its target symptoms depressed mood, anxiety and insomnia." | 5.10 | Confirmation of the neurophysiologically predicted therapeutic effects of trazodone on its target symptoms depression, anxiety and insomnia by postmarketing clinical studies with a controlled-release formulation in depressed outpatients. ( Anderer, P; Arnold, O; Saletu, B; Saletu-Zyhlarz, GM, 2003) |
| "05), while more trazodone-treated patients reported somnolence and dizziness (p less than or equal to ." | 5.07 | Fluoxetine versus trazodone: efficacy and activating-sedating effects. ( Beasley, CM; Bosomworth, JC; Dornseif, BE; Pultz, JA; Sayler, ME, 1991) |
| "To establish the differential indication of trazodone and to find the predictors of its efficacy, we conducted a study in which 45 patients with major depressive disorder and 75 patients with acute schizophrenia were randomly assigned under double-blind conditions to either 400 mg trazodone daily, 150 mg amitriptyline daily, 20 mg haloperidol daily, or placebo daily." | 5.06 | Experimental examination of trazodone. ( Klieser, E; Lehmann, E, 1989) |
| " Twenty-eight inpatients with a diagnosis of endogenous depression received either trazodone, imipramine, or placebo." | 5.04 | Trazodone, a new antidepressant: efficacy and safety in endogenous depression. ( Kellams, JJ; Klapper, MH; Small, JG, 1979) |
| "Due diligence and meticulous attention to detail needs to be exercised to uncover drug interactions as potential causes of lethal and nonlethal patient symptomatology, as in this case of syncope caused by concomitant use of trazodone and a widely prescribed medication, omeprazole." | 4.91 | Trazodone and omeprazole interaction causing frequent second-degree Mobitz type 1 atrioventricular (AV) block (Wenckebach phenomenon) and syncope: a case report and literature review. ( Akinseye, OA; Alfishawy, M; Bakshi, S; Radparvar, F, 2015) |
| "A single dose of trazodone before transport reduced signs of stress during veterinary visits for dogs in the present study and may be useful as an anti-anxiety medication for similarly affected dogs, potentially resulting in higher-quality clinical examinations and improved patient welfare." | 4.12 | Effects of trazodone on behavioral and physiological signs of stress in dogs during veterinary visits: a randomized double-blind placebo-controlled crossover clinical trial. ( Bain, MJ; Borchardt, MR; Kim, SA; Lee, K; Stelow, EA, 2022) |
| "Trazodone is an anxiolytic used PO to decrease anxiety in dogs." | 4.12 | Effects of trazodone administration on the neurologic examination in healthy dogs. ( Cameron, S; Lueck, LC; Zidan, N, 2022) |
| " Trazodone turned out to be an efficacious medicine in the therapy of adjustment disorders." | 3.73 | [The efficacy and safety of trazodone in the treatment of adjustment disorders--naturalistic research]. ( Florkowski, A; Gałecki, P; Zboralski, K, 2005) |
| "We describe a patient treated with trazodone, amitriptyline and lithium carbonate who developed anxiety, restlessness, tremor, myoclonus, hyperreflexia, diaphoresis, rigidity and hyperthermia." | 3.69 | A case of serotonin syndrome induced by concomitant treatment with low-dose trazodone and amitriptyline and lithium. ( Abe, T; Ishiguro, T; Nisijima, K; Shimizu, M, 1996) |
| " After 3 days, administration of tramadol was discontinued, and the trazodone dosage was increased (approx 7 mg/kg [3." | 2.79 | Use of trazodone to facilitate postsurgical confinement in dogs. ( Griffith, E; Gruen, ME; Hamilton, A; Roe, SC; Sherman, BL, 2014) |
| "An additional insomnia analysis assessed whether the efficacy of TzCOAD is influenced by improvements in insomnia or baseline severity of insomnia." | 2.74 | The efficacy and tolerability of once-daily controlled-release trazodone for depressed mood, anxiety, insomnia, and suicidality in major depressive disorder. ( Gibertini, M; Gossen, ER; Rozova, A; Sheehan, DV, 2009) |
| "Trazodone is an antidepressant of the serotonin (5-HT2) antagonist and reuptake inhibitor class, and has been considered to act as a multifunctional drug." | 2.46 | [Trazodone--its multifunctional mechanism of action and clinical use]. ( Frecska, E, 2010) |
| "Antidepressant-induced jitteriness/anxiety syndrome is characterized as anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia, and (hypo)mania, which appear immediately after initiation or increased dosage of an antidepressant." | 1.91 | Jitteriness/anxiety syndrome caused by coadministration of celecoxib, a selective COX-2 inhibitor, with escitalopram and trazodone in a patient with depression and spondylolisthesis. ( Kanno, M; Noto, K; Shirata, T; Suzuki, A; Yano, S, 2023) |
| "Obstructive sleep apnea (OSA) is a highly prevalent type of sleep-disordered breathing, which is often comorbid with affective disorders such as anxiety." | 1.91 | Successful treatment of auto-trilevel positive airway pressure plus trazodone for obstructive sleep apnea complicated by anxiety disorder: a case report. ( He, X; Lang, Q; Pei, ZM; Yan, HY, 2023) |
| "Trazodone is a drug that acts a weak, but specific, inhibitor of the uptake of 3H-serotonin and is generally used for its antidepressant effects." | 1.29 | Trazodone: a non-hormonal alternative for neurovegetative climacteric symptoms. ( Albertazzi, P; Bonaccorsi, G; Campobasso, C; Dossi, L; Mollica, G; Pansini, F; Porto, S; Zanotti, L, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (30.00) | 18.7374 |
| 1990's | 6 (15.00) | 18.2507 |
| 2000's | 8 (20.00) | 29.6817 |
| 2010's | 10 (25.00) | 24.3611 |
| 2020's | 4 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, SA | 1 |
| Borchardt, MR | 1 |
| Lee, K | 1 |
| Stelow, EA | 1 |
| Bain, MJ | 1 |
| Lueck, LC | 1 |
| Cameron, S | 1 |
| Zidan, N | 1 |
| Shirata, T | 1 |
| Yano, S | 1 |
| Noto, K | 1 |
| Kanno, M | 1 |
| Suzuki, A | 1 |
| He, X | 1 |
| Lang, Q | 1 |
| Pei, ZM | 1 |
| Yan, HY | 1 |
| Osváth, P | 1 |
| Gruen, ME | 4 |
| Roe, SC | 2 |
| Griffith, E | 3 |
| Hamilton, A | 2 |
| Sherman, BL | 4 |
| Petty, MC | 1 |
| Akinseye, OA | 1 |
| Alfishawy, M | 1 |
| Radparvar, F | 1 |
| Bakshi, S | 1 |
| Stevens, BJ | 1 |
| Frantz, EM | 1 |
| Orlando, JM | 1 |
| Harden, LB | 1 |
| Amin, R | 1 |
| Kast, RE | 1 |
| Sheehan, DV | 1 |
| Rozova, A | 1 |
| Gossen, ER | 1 |
| Gibertini, M | 1 |
| Frecska, E | 1 |
| Calandre, EP | 1 |
| Morillas-Arques, P | 1 |
| Molina-Barea, R | 1 |
| Rodriguez-Lopez, CM | 1 |
| Rico-Villademoros, F | 1 |
| Pae, CU | 1 |
| Lee, CU | 1 |
| Lee, SJ | 1 |
| Lee, C | 1 |
| Paik, IH | 1 |
| Saletu-Zyhlarz, GM | 1 |
| Anderer, P | 1 |
| Arnold, O | 1 |
| Saletu, B | 1 |
| Gałecki, P | 1 |
| Zboralski, K | 1 |
| Florkowski, A | 1 |
| Hsiao, SY | 1 |
| Cherng, CF | 1 |
| Yang, YK | 1 |
| Yeh, TL | 1 |
| Yu, L | 1 |
| Ripoll, N | 1 |
| Hascoët, M | 1 |
| Bourin, M | 1 |
| Koval'chuk, VV | 1 |
| Lebert, F | 1 |
| Pasquier, F | 1 |
| Petit, H | 1 |
| Pansini, F | 1 |
| Albertazzi, P | 1 |
| Bonaccorsi, G | 1 |
| Zanotti, L | 1 |
| Porto, S | 1 |
| Dossi, L | 1 |
| Campobasso, C | 1 |
| Mollica, G | 1 |
| Nisijima, K | 1 |
| Shimizu, M | 1 |
| Abe, T | 1 |
| Ishiguro, T | 1 |
| Razavi, D | 1 |
| Kormoss, N | 1 |
| Collard, A | 1 |
| Farvacques, C | 1 |
| Delvaux, N | 1 |
| Kellams, JJ | 1 |
| Klapper, MH | 1 |
| Small, JG | 1 |
| Fedeli, S | 1 |
| Ferri, FA | 1 |
| Fogari, R | 1 |
| Roccatagliata, G | 2 |
| Gandolfo, C | 1 |
| Cammarata, S | 1 |
| De Martini, I | 1 |
| Arcuri, T | 1 |
| Loeb, C | 1 |
| Besio, G | 1 |
| Allori, L | 1 |
| Catanese, B | 1 |
| Cioli, V | 1 |
| Interdonato, N | 1 |
| Nicoletti, F | 1 |
| Wheatley, D | 1 |
| Beasley, CM | 1 |
| Dornseif, BE | 1 |
| Pultz, JA | 1 |
| Bosomworth, JC | 1 |
| Sayler, ME | 1 |
| Boylan, K | 1 |
| Cazzullo, CL | 1 |
| Klieser, E | 1 |
| Lehmann, E | 1 |
| Pretorius, HW | 1 |
| Patel, HC | 1 |
| Bruza, D | 1 |
| Yeragani, V | 1 |
| Smith, TM | 1 |
| Suckow, RF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Open Label Trial Concerning the Effectiveness of Trazodone in the Treatment of Fibromyalgia (Phase I) and Its Augmentation With Pregabalin in Trazodone Partial Responders (Phase II)[NCT00791739] | Phase 4 | 66 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for trazodone and Anxiety
| Article | Year |
|---|---|
[Current treatment of depression and agitation in the elderly -- clinical use of trazodone].
Topics: Aged; Aged, 80 and over; Anti-Anxiety Agents; Antidepressive Agents; Antidepressive Agents, Second-G | 2013 |
Trazodone and omeprazole interaction causing frequent second-degree Mobitz type 1 atrioventricular (AV) block (Wenckebach phenomenon) and syncope: a case report and literature review.
Topics: Anti-Anxiety Agents; Anxiety; Atrioventricular Block; Diagnosis, Differential; Drug Interactions; El | 2015 |
[Trazodone--its multifunctional mechanism of action and clinical use].
Topics: Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Anxiety; Depressive Disorder, Major; | 2010 |
New treatment for anxious depression syndrome.
Topics: Anxiety; Depression; Humans; Syndrome; Trazodone | 1989 |
14 trials available for trazodone and Anxiety
| Article | Year |
|---|---|
Use of trazodone to facilitate postsurgical confinement in dogs.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Anxiety Disorders; Dog Diseases; Dogs; Orthopedic Procedures; | 2014 |
Efficacy of a single dose of trazodone hydrochloride given to cats prior to veterinary visits to reduce signs of transport- and examination-related anxiety.
Topics: Animal Welfare; Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Cats; Cross-Over Studies; T | 2016 |
The efficacy and tolerability of once-daily controlled-release trazodone for depressed mood, anxiety, insomnia, and suicidality in major depressive disorder.
Topics: Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Anxiety; Delayed-Action Prepa | 2009 |
Trazodone plus pregabalin combination in the treatment of fibromyalgia: a two-phase, 24-week, open-label uncontrolled study.
Topics: Adult; Analgesics; Analysis of Variance; Anti-Anxiety Agents; Antidepressive Agents, Second-Generati | 2011 |
Confirmation of the neurophysiologically predicted therapeutic effects of trazodone on its target symptoms depression, anxiety and insomnia by postmarketing clinical studies with a controlled-release formulation in depressed outpatients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Anxiety; Bipol | 2003 |
[Pharmacologic correction of psycho-emotive disorders in the rehabilitation of patients after removal of brain tumors].
Topics: Adult; Alprazolam; Amitriptyline; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Brain Neoplas | 2007 |
Behavioral effects of trazodone in Alzheimer's disease.
Topics: Affective Symptoms; Aged; Aggression; Alzheimer Disease; Anxiety; Female; Follow-Up Studies; Humans; | 1994 |
Comparative study of the efficacy and safety of trazodone versus clorazepate in the treatment of adjustment disorders in cancer patients: a pilot study.
Topics: Adjustment Disorders; Adult; Aged; Anti-Anxiety Agents; Anxiety; Breast Neoplasms; Clorazepate Dipot | 1999 |
Trazodone, a new antidepressant: efficacy and safety in endogenous depression.
Topics: Adult; Aged; Anxiety; Clinical Trials as Topic; Depression; Double-Blind Method; Female; Humans; Imi | 1979 |
Blockade of acute opiate-withdrawal symptoms by trazodone treatment.
Topics: Acute Disease; Anxiety; Clinical Trials as Topic; Heroin Dependence; Humans; Piperazines; Substance | 1979 |
[Clinical trial of a new perparation with psychotropic action].
Topics: Adult; Aged; Anxiety; Clinical Trials as Topic; Depression; Drug Evaluation; Female; Humans; Male; M | 1975 |
Evaluation of trazodone in the treatment of anxiety.
Topics: Adolescent; Adult; Anxiety; Chlordiazepoxide; Clinical Trials as Topic; Female; Humans; Male; Middle | 1976 |
Fluoxetine versus trazodone: efficacy and activating-sedating effects.
Topics: Adult; Akathisia, Drug-Induced; Ambulatory Care; Anxiety; Depressive Disorder; Dizziness; Double-Bli | 1991 |
Experimental examination of trazodone.
Topics: Adult; Amitriptyline; Anxiety; Depression; Depressive Disorder; Double-Blind Method; Female; Haloper | 1989 |
22 other studies available for trazodone and Anxiety
| Article | Year |
|---|---|
Effects of trazodone on behavioral and physiological signs of stress in dogs during veterinary visits: a randomized double-blind placebo-controlled crossover clinical trial.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Dogs; Double-Blind Method; Heart Rate; Hospitals, Animal; Tra | 2022 |
Effects of trazodone administration on the neurologic examination in healthy dogs.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Dogs; Neurologic Examination; Trazodone | 2022 |
Jitteriness/anxiety syndrome caused by coadministration of celecoxib, a selective COX-2 inhibitor, with escitalopram and trazodone in a patient with depression and spondylolisthesis.
Topics: Antidepressive Agents; Anxiety; Celecoxib; Cyclooxygenase 2 Inhibitors; Escitalopram; Female; Humans | 2023 |
Successful treatment of auto-trilevel positive airway pressure plus trazodone for obstructive sleep apnea complicated by anxiety disorder: a case report.
Topics: Anxiety; Anxiety Disorders; Female; Humans; Middle Aged; Sleep Apnea Syndromes; Sleep Apnea, Obstruc | 2023 |
Use of trazodone to facilitate postsurgical confinement in dogs.
Topics: Animals; Anxiety; Anxiety Disorders; Dog Diseases; Orthopedic Procedures; Trazodone | 2014 |
The authors respond.
Topics: Animals; Anxiety; Anxiety Disorders; Dog Diseases; Orthopedic Procedures; Trazodone | 2014 |
Fluoxetine and Trazodone Combination Pharmacotherapy Resulting in Severe Irritability, Anger, Anxiety, and Anorexia: Probable Adverse Drug Interaction.
Topics: Adult; Anger; Anorexia; Antidepressive Agents, Second-Generation; Anxiety; Drug Interactions; Drug T | 2016 |
Trazodone generates m-CPP: in 2008 risks from m-CPP might outweigh benefits of trazodone.
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety; Biotransformation; Brain; Dose-Response | 2009 |
Animal behavior case of the month: thunderstorm phobia.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Behavior Therapy; Behavior, Animal; Dog Diseases; Dogs; Male; | 2012 |
Association of low dose trazodone treatment with aggravated angle-closure glaucoma.
Topics: Anti-Anxiety Agents; Anxiety; Dose-Response Relationship, Drug; Female; Glaucoma, Angle-Closure; Hum | 2003 |
[The efficacy and safety of trazodone in the treatment of adjustment disorders--naturalistic research].
Topics: Adjustment Disorders; Adult; Affect; Aggression; Anxiety; Depression; Female; Humans; Male; Psychiat | 2005 |
Prenatal bupropion exposure enhances the cocaine reward and stress susceptibility in adult mice.
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety; Bupropion; Citalopram; Cocaine; Conditio | 2005 |
The four-plates test: anxiolytic or analgesic paradigm?
Topics: Analgesics; Analgesics, Opioid; Animals; Anti-Anxiety Agents; Antidepressive Agents, Second-Generati | 2006 |
Trazodone: a non-hormonal alternative for neurovegetative climacteric symptoms.
Topics: Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Anxiety; Climacteric; Contraindicatio | 1995 |
A case of serotonin syndrome induced by concomitant treatment with low-dose trazodone and amitriptyline and lithium.
Topics: Amitriptyline; Anxiety; Bipolar Disorder; Humans; Lithium; Male; Middle Aged; Trazodone | 1996 |
[Treatment of depression in the menopause with trazodone].
Topics: Adjustment Disorders; Anxiety; Depression; Female; Humans; Menopause; Middle Aged; Piperazines; Traz | 1979 |
[Variations in the urinary level of MHPG in depressive syndromes].
Topics: Adult; Age Factors; Aged; Antidepressive Agents, Tricyclic; Anxiety; Depression; Depressive Disorder | 1979 |
A study of serum levels of trazodone produced in man following single or repeated oral administrations.
Topics: Administration, Oral; Anxiety; Depression; Dose-Response Relationship, Drug; Female; Humans; Male; P | 1978 |
Persistent dystonia associated with buspirone.
Topics: Anxiety; Buspirone; Depression; Drug Therapy, Combination; Dystonia; Female; Follow-Up Studies; Huma | 1990 |
Other forms of treatment for anxiety.
Topics: Adrenergic beta-Antagonists; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Anxiety; Behavio | 1985 |
Myoclonus with trazodone.
Topics: Adult; Anxiety; Female; Humans; Myoclonus; Trazodone | 1988 |
Trazodone and m-chlorophenylpiperazine. Concentration in brain and receptor activity in regions in the brain associated with anxiety.
Topics: Animals; Anxiety; Brain; Clonidine; Flunitrazepam; In Vitro Techniques; Isomerism; Male; Membranes; | 1985 |